(Sharecast News) - Sanofi reported stronger-than-expected third-quarter earnings on Friday, driven by early vaccine sales and robust performance from its anti-inflammatory drug Dupixent.
Quarterly business operating income, excluding one-off items, rose 14.4% to €4.6bn, surpassing analysts' projections of €4bn.

Earnings per share reached €2.86, also beating estimates, with total revenue...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE